Piper Jaffray Companies assumed coverage on shares of TELA Bio (NASDAQ:TELA) in a research note published on Tuesday morning, Benzinga reports. The firm issued an overweight rating and a $17.00 target price on the stock.
TELA opened at $12.96 on Tuesday. TELA Bio has a 12-month low of $10.78 and a 12-month high of $15.05.
In related news, Director Matt Zuga acquired 86,121 shares of TELA Bio stock in a transaction on Friday, November 8th. The stock was purchased at an average cost of $12.09 per share, with a total value of $1,041,202.89. Also, major shareholder Orbimed Advisors Llc acquired 384,615 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was bought at an average price of $12.09 per share, for a total transaction of $4,649,995.35.
TELA Bio, Inc, a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. It offers reinforced tissue matrix products for a variety of reconstruction procedures, including hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery.
Further Reading: What is FinTech?
Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.